AI Engines For more Details: Perplexity Kagi Labs You
Anxiolytic Effect: Buspirone acts as an anxiolytic, meaning it helps to alleviate symptoms of anxiety. It does so by selectively targeting serotonin receptors (5-HT1A receptors) and modulating serotonin activity in the brain.
Non-Sedating: Unlike benzodiazepines, another class of drugs used to treat anxiety, buspirone does not typically cause sedation or impair cognitive function. This makes it a preferred option for individuals who need relief from anxiety symptoms without experiencing drowsiness or mental fog.
Gradual Onset of Action: Buspirone's anxiolytic effects may not be immediately noticeable. It usually takes several weeks of consistent use for the full therapeutic effect to be achieved. Therefore, it is not suitable for the acute management of anxiety or panic attacks.
Lacks Potential for Dependence: Buspirone is not associated with the development of physical dependence or withdrawal symptoms, unlike benzodiazepines. This makes it a safer option for long-term use in patients with chronic anxiety disorders.
Limited Efficacy in Panic Disorder: While buspirone is effective for treating generalized anxiety disorder, it may have limited efficacy in managing panic disorder or acute anxiety episodes characterized by panic attacks. Other medications, such as selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines, are often preferred for these conditions.
Side Effects: Common side effects of buspirone may include dizziness, headache, nausea, restlessness, insomnia, and lightheadedness. These side effects are usually mild and transient, but they may persist in some individuals.
Contraindications: Buspirone should not be used in patients with a known hypersensitivity to the drug. It may also interact with certain medications, particularly monoamine oxidase inhibitors (MAOIs), which can lead to potentially dangerous serotonin syndrome.
Pregnancy and Lactation: The safety of buspirone use during pregnancy and breastfeeding has not been well-established. It should be used with caution in pregnant or lactating women, and the potential risks and benefits should be carefully considered.
Dosage and Administration: Buspirone is typically taken orally, with or without food. The dosage may vary depending on the individual's age, medical condition, and response to treatment. It is important to follow the prescribed dosage and instructions provided by a healthcare professional.
Monitoring: Patients taking buspirone may require periodic monitoring to assess the response to treatment and monitor for any adverse effects. Adjustments to the dosage may be necessary based on individual needs and tolerability.
Rank | Probiotic | Impact |
---|---|---|
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
0 | 1 | Roseburia rectibacter | species | Decreases |
0 | 1 | Butyrivibrio crossotus | species | Decreases |
0 | 1 | Ligilactobacillus ruminis | species | Decreases |
0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.1 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
Allergies | 0 | 0 | |
Alzheimer's disease | 0.4 | -0.4 | |
Anorexia Nervosa | 0.1 | -0.1 | |
Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
Asthma | 0.2 | 0.1 | 1 |
Atherosclerosis | 0.4 | -0.4 | |
Autism | 0.2 | 0.1 | 1 |
Autoimmune Disease | 0.1 | -0.1 | |
Bipolar Disorder | 0 | 0.2 | 0 |
Brain Trauma | 0.1 | -0.1 | |
Cancer (General) | 0.6 | -0.6 | |
Carcinoma | 0 | 0 | |
Celiac Disease | 0.3 | 0.3 | |
Cerebral Palsy | 0.1 | -0.1 | |
Chronic Fatigue Syndrome | 0.6 | 0.6 | |
Chronic Kidney Disease | 0 | 0.3 | 0 |
Chronic Lyme | 0.1 | -0.1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | -0.1 | |
Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
Cognitive Function | 0.1 | -0.1 | |
Colorectal Cancer | 0.1 | 0.1 | 0 |
Constipation | 0.1 | -0.1 | |
Coronary artery disease | 0.1 | -0.1 | |
COVID-19 | 0.1 | 0.4 | -3 |
Crohn's Disease | 0.2 | 0.1 | 1 |
cystic fibrosis | 0.1 | -0.1 | |
deep vein thrombosis | 0.1 | -0.1 | |
Depression | 1 | 1 | 0 |
Endometriosis | 0.1 | -0.1 | |
Fibromyalgia | 0.2 | 0.2 | |
Functional constipation / chronic idiopathic constipation | 0.3 | 0.1 | 2 |
gallstone disease (gsd) | 0.1 | -0.1 | |
Generalized anxiety disorder | 0 | 0 | |
Graves' disease | 0.1 | -0.1 | |
Hashimoto's thyroiditis | 0.1 | 0.1 | |
Heart Failure | 0.1 | -0.1 | |
High Histamine/low DAO | 0.1 | 0.1 | |
hypertension (High Blood Pressure | 0.1 | -0.1 | |
Hypothyroidism | 0 | 0 | |
IgA nephropathy (IgAN) | 0 | 0.1 | 0 |
Inflammatory Bowel Disease | 0.1 | 0.4 | -3 |
Insomnia | 0.1 | -0.1 | |
Irritable Bowel Syndrome | 0.1 | 0.1 | 0 |
ischemic stroke | 0.1 | -0.1 | |
Liver Cirrhosis | 0.2 | 0.1 | 1 |
Long COVID | 0.1 | 0.1 | 0 |
Low bone mineral density | 0.1 | -0.1 | |
ME/CFS without IBS | 0.1 | 0.1 | |
Menopause | 0.1 | 0.1 | 0 |
Metabolic Syndrome | 0.3 | 0.1 | 2 |
Mood Disorders | 1 | 0.8 | 0.25 |
Multiple Sclerosis | 0.1 | 0.1 | 0 |
myasthenia gravis | 0.1 | -0.1 | |
neuropathic pain | 0 | 0.1 | 0 |
Neuropathy (all types) | 0 | 0.1 | 0 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.1 | 2 |
NonCeliac Gluten Sensitivity | 0 | 0 | |
Obesity | 0.1 | 0.8 | -7 |
Osteoporosis | 0.2 | 0.2 | |
Parkinson's Disease | 0.2 | 0.4 | -1 |
Polycystic ovary syndrome | 0.1 | 0.1 | 0 |
Psoriasis | 0.1 | -0.1 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.2 | 0.1 | 1 |
Rosacea | 0.1 | -0.1 | |
Schizophrenia | 0 | 0.1 | 0 |
Sleep Apnea | 0.2 | -0.2 | |
Stress / posttraumatic stress disorder | 0.1 | 0.2 | -1 |
Systemic Lupus Erythematosus | 0 | 0.1 | 0 |
Type 1 Diabetes | 0.1 | -0.1 | |
Type 2 Diabetes | 0.4 | 0.6 | -0.5 |
Ulcerative colitis | 0.5 | 0.1 | 4 |
Unhealthy Ageing | 0 | 0.1 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]